India’s first approved dengue vaccine is moving from regulatory clearance toward commercial access. Takeda Biopharmaceuticals India and Dr Reddy’s Laboratories have agreed an exclusive private-market deal to promote and distribute QDENGA, with availability expected in the first half of 2027 once remaining local processes are completed.
The Central Drugs Standard Control Organisation granted marketing authorisation for QDENGA in July 2026 for people aged 4 to 60, making it the first dengue vaccine cleared for use in India. The product is a live attenuated tetravalent vaccine, also known as TAK-003, built on a DENV-2 backbone and given as two 0.5 ml doses three months apart.
What the Dr Reddy’s deal covers
Under the agreement, Dr Reddy’s will have exclusive rights to promote and distribute QDENGA in India’s private paediatric and adult vaccination market. Takeda retains rights related to the public market, along with brand ownership and medical oversight. Manufacturing, importation and legal ownership remain with Takeda under the structure described in company and trade reporting.
That split matters for how Indians are likely to encounter the vaccine first. Public immunisation programme inclusion is described as a longer-term ambition. Private clinics and hospitals are the interim access path while broader public-sector decisions remain open.
Pricing has not been announced. Takeda has said it is premature to speculate on cost before the commercial launch window.
Why QDENGA is a first for India
Dengue has long been a seasonal and urban public-health pressure in India, with repeated outbreaks straining hospitals and municipal response systems. Until the July 2026 CDSCO decision, India did not have an approved dengue vaccine on the market. QDENGA’s clearance therefore fills a regulatory gap even before the first vials reach private channels.
Globally, the vaccine is already established. It is approved in 42 countries, is WHO-prequalified, and more than 24 million doses have been distributed worldwide, according to figures cited via PIB-linked coverage of the Indian clearance and partnership. Those international numbers do not automatically translate into Indian public-programme uptake, but they are part of why the CDSCO authorisation and the distribution pact drew attention across business and health desks.
What Dr Reddy’s is signalling
Dr Reddy’s framed the partnership as an expansion of its vaccines footprint. MV Ramana, the company’s CEO for Global Generics, said: “As the second-largest vaccine player in India, we believe the introduction of India’s first approved dengue vaccine is an important development for the country’s healthcare landscape…”
The quote underlines a commercial and public-health pitch at once: Dr Reddy’s brings private-market reach; Takeda brings the licensed product and medical governance. For patients and clinicians, the practical questions will be availability by city and clinic network, cold-chain readiness, and how counselling is handled for a two-dose schedule spaced three months apart.
What still has to happen before H1 2027
Expected availability in the first half of 2027 remains subject to remaining local processes. Reporting around the deal points to steps such as registration follow-through, import licensing and quality-release workflows before commercial supply can start. Until those are done, the July 2026 marketing authorisation is necessary but not sufficient for patients to book a shot.
The private-market focus also leaves open how, when and whether QDENGA enters government procurement or national immunisation planning. Company language treats that as a longer horizon rather than a near-term launch feature.
The bottom line for readers
For now, the verified story is narrower and still significant: India’s first approved dengue vaccine has a private-market distribution partner, a target window in H1 2027, a defined age band of 4–60, a two-dose schedule, and no public price yet. Whether that becomes a mass public-health tool will depend on decisions beyond this commercial agreement. The deal, however, marks the clearest path yet for Indian patients to access a dengue vaccine through private care once supply clears the remaining local gates.